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We describe a recently recognized disease entity, limbic-predominant age-related TDP-43 encephalopathy (LATE). LATE neuro-
pathological change (LATE-NC) is defined by a stereotypical TDP-43 proteinopathy in older adults, with or without coexisting
hippocampal sclerosis pathology. LATE-NC is a common TDP-43 proteinopathy, associated with an amnestic dementia syndrome
that mimicked Alzheimer’s-type dementia in retrospective autopsy studies. LATE is distinguished from frontotemporal lobar de-
generation with TDP-43 pathology based on its epidemiology (LATE generally affects older subjects), and relatively restricted
neuroanatomical distribution of TDP-43 proteinopathy. In community-based autopsy cohorts, 25% of brains had sufficient
burden of LATE-NC to be associated with discernible cognitive impairment. Many subjects with LATE-NC have comorbid
brain pathologies, often including amyloid-b plaques and tauopathy. Given that the ‘oldest-old’ are at greatest risk for LATE-
NC, and subjects of advanced age constitute a rapidly growing demographic group in many countries, LATE has an expanding but
under-recognized impact on public health. For these reasons, a working group was convened to develop diagnostic criteria for
LATE, aiming both to stimulate research and to promote awareness of this pathway to dementia. We report consensus-based
recommendations including guidelines for diagnosis and staging of LATE-NC. For routine autopsy workup of LATE-NC, an
anatomically-based preliminary staging scheme is proposed with TDP-43 immunohistochemistry on tissue from three brain areas,
reflecting a hierarchical pattern of brain involvement: amygdala, hippocampus, and middle frontal gyrus. LATE-NC appears to
affect the medial temporal lobe structures preferentially, but other areas also are impacted. Neuroimaging studies demonstrated
that subjects with LATE-NC also had atrophy in the medial temporal lobes, frontal cortex, and other brain regions. Genetic studies
have thus far indicated five genes with risk alleles for LATE-NC: GRN, TMEM106B, ABCC9, KCNMB2, and APOE. The
discovery of these genetic risk variants indicate that LATE shares pathogenetic mechanisms with both frontotemporal lobar
degeneration and Alzheimer’s disease, but also suggests disease-specific underlying mechanisms. Large gaps remain in our under-
standing of LATE. For advances in prevention, diagnosis, and treatment, there is an urgent need for research focused on LATE,
including in vitro and animal models. An obstacle to clinical progress is lack of diagnostic tools, such as biofluid or neuroimaging
biomarkers, for ante-mortem detection of LATE. Development of a disease biomarker would augment observational studies
seeking to further define the risk factors, natural history, and clinical features of LATE, as well as eventual subject recruitment
for targeted therapies in clinical trials.
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Introduction
Transactive response DNA binding protein of 43 kDa
(TDP-43) proteinopathy in limbic brain structures is com-
monly observed in subjects past 80 years of age. This pro-
teinopathy has been associated with substantial cognitive
impairment that mimicked Alzheimer’s disease clinical syn-
drome in retrospective studies. Despite evidence from many
sources attesting to the public health impact of age-related
TDP-43 proteinopathy, there is as yet no consensus-based
nomenclature. To address this problem, we propose new
terminology: limbic-predominant age-related TDP-43 en-
cephalopathy (LATE). Guidelines are suggested for the aut-
opsy evaluation and staging of LATE neuropathological
change (LATE-NC). We review the medical literature per-
taining to LATE, including cognitive manifestations, neu-
roimaging, public health impact, and genetics. The
importance of LATE as a contributing factor in neurode-
generation is stressed, as are the needs for specific LATE
biomarker development, TDP-43 focused drug discovery,
and eventual clinical trials. We conclude by highlighting
important knowledge gaps and potential future directions
for research on LATE. Summary points are presented in
Box 1.
Background
There is growing awareness that Alzheimer’s disease neuro-
pathological change (ADNC) is only one of multiple neuro-
pathological substrates associated with amnestic mild
cognitive impairment and the Alzheimer’s clinical syndrome
in the aged population (Korczyn, 2002; Zekry et al., 2002;
Bennett et al., 2006; Jellinger and Attems, 2007; Schneider
et al., 2007; Crary et al., 2014; Murray et al., 2014;
Rahimi and Kovacs, 2014; James et al., 2016). Recent stu-
dies have gathered rich clinical data from large groups of
subjects across a spectrum of cognitive states, correlated
these clinical findings with new pathological markers at
autopsy, and then analysed the data using powerful statis-
tical methods. These studies have indicated that the diseases
of aged human brains are complex: multiple comorbid
pathologies are the norm, and there is substantial interin-
dividual variation in neuropathological phenotypes
(Neuropathology Group. Medical Research Council
Cognitive and Aging, 2001; Brayne et al., 2009; Kovacs
et al., 2013; Murray et al., 2014; Rahimi and Kovacs,
2014; White et al., 2016; Abner et al., 2017; Kapasi
et al., 2017; Suemoto et al., 2017; Tanskanen et al.,
2017; Robinson et al., 2018b, c). While there is a strong
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association between severe ADNC and cognitive impair-
ment in all age groups (Nelson et al., 2009; Abner et al.,
2011), subjects who die after 80 years of age often have
exhibited cognitive decline exceeding expectation given the
severity of ADNC (Kawas and Corrada, 2006; Savva et al.,
2009; Nelson et al., 2012). LATE-NC is an important con-
tributor to this apparent clinicopathological mismatch (see
below).
Historically, the first-recognized pathological manifest-
ation of LATE was profound hippocampal neuron loss
and gliosis, collectively termed hippocampal sclerosis. In a
landmark study, Dickson et al. (1994) identified 13 elderly
subjects with dementia and hippocampal sclerosis, yet who
lacked substantial ADNC. Other larger autopsy series that
included subjects with dementia and hippocampal sclerosis
were later reported (Crystal et al., 2000; Barker et al.,
2002; Leverenz et al., 2002; White et al., 2002; Zarow
et al., 2005; Attems and Jellinger, 2006; Brayne et al.,
2009). In 2006, phosphorylated TDP-43 was discovered
as the disease protein in the ubiquitylated inclusions that
are signatures of amyotrophic lateral sclerosis (ALS) and
most cases of frontotemporal lobar degeneration (FTLD),
known as FTLD-TDP (Neumann et al., 2006; Cairns et al.,
2007a). TDP-43 protein, encoded by the TARDBP gene
(Ou et al., 1995), is a protein that binds to RNA and
DNA as well as to other proteins, and serves multiple func-
tions in gene expression regulation at the levels of both
transcription and translation (Cohen et al., 2011; Guo
and Shorter, 2017). Expressed in most human tissues and
cell types, TDP-43 is predominantly non-phosphorylated
and localized mostly within nuclei, while in disease states
the protein is phosphorylated and often translocated to the
cytoplasm (Neumann et al., 2006).
Following the detection of TDP-43 proteinopathy in
FTLD-TDP and in the large majority of ALS cases
(Mackenzie et al., 2007), TDP-43 proteinopathy was also
discovered in the brains of subjects over age 80 years with-
out FTLD or ALS, but often with comorbid hippocampal
sclerosis and/or ADNC (Amador-Ortiz et al., 2007a, b). In
subjects with ADNC, LATE-NC represents a common
comorbid lesion that lowers the threshold for developing
dementia (Josephs et al., 2014b, 2015). In retrospective
studies, age-related TDP-43 proteinopathy has been asso-
ciated with a progressive amnestic syndrome that mimicked
the Alzheimer’s clinical syndrome (Pao et al., 2011;
Brenowitz et al., 2014). TDP-43 proteinopathy, hippocam-
pal sclerosis pathology, and the associated amnestic demen-
tia increases with advanced age, while the prevalence of
severe ADNC decreases in extreme old age (Nelson et al.,
2011a, b, 2013; Brenowitz et al., 2014). The presence of
pathological TDP-43 in these cases suggests a novel disease
mechanism in older adults. As there is currently no univer-
sally agreed upon terminology or staging system for
common age-related TDP-43 proteinopathy, this condition
is under-studied and not well recognized even among inves-
tigators in the field of dementia research. The promotion of
research and increasing awareness of this disease are the
primary motivations for developing the new term LATE,
and for the recommendations that follow.
LATE neuropathological changes
LATE-NC is a TDP-43 proteinopathy of advanced age,
especially in subjects older than age 80. Following the con-
vention proposed by a working group for the neuropatho-
logical criteria of Alzheimer’s disease (Montine et al.,
2012), we use LATE to refer to the disease, and LATE-
NC as the term to indicate LATE neuropathological
changes. The term LATE is intended to encompass several
previously used designations related to TDP-43 proteinopa-
thy that may be associated with cognitive impairment,
including hippocampal sclerosis, hippocampal sclerosis of
ageing, hippocampal sclerosis dementia, cerebral age-
related TDP-43 with sclerosis, and TDP-43 pathologies in
the elderly (for reviews see Kuslansky et al., 2004; Lippa
and Dickson, 2004; Nelson et al., 2013, 2016b; Dutra
et al., 2015).
Box 1 LATE and LATE-NC summary
points
 LATE-NC features
 A sampling and staging system for routine autopsy diagnosis
is proposed to characterize the anatomical distribution of
TDP-43 proteinopathy
 Stage 1: amygdala only
 Stage 2: + hippocampus
 Stage 3: + middle frontal gyrus
 Hippocampal sclerosis pathology may be observed (and
should be reported), but is neither necessary nor sufficient
for diagnosis of LATE-NC
 LATE-NC is present in 420% (up to 50%) of individuals past
age 80 years according to large community-based autopsy
series
 LATE is associated with substantial disease-specific cognitive
impairment, usually an amnestic dementia syndrome (‘dementia
of the Alzheimer’s type’)
 The overall public health impact of LATE is on the same order
of magnitude as Alzheimer’s disease neuropathological changes;
the diseases are often comorbid, but which pathology is more
severe varies greatly between individuals
 Genetic risk factors for LATE have some overlap with FTLD-
TDP and with Alzheimer’s disease
 There is no molecule-specific biomarker for LATE. This is an
important area of need for use in clinical trials (including as a
potential exclusion criterion for Alzheimer’s disease clinical
trials) and longitudinal studies of the clinical and pathological
progression of LATE
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‘TDP-43 proteinopathy’ refers to loss of normal nuclear
TDP-43 immunoreactivity, with TDP-43 protein ‘inclusion
bodies’ in the neuronal cytoplasm, as well as abnormal
TDP-43 accumulation (much of it phosphorylated) in
nuclei and cell processes (neurites) of neurons and in oligo-
dendroglia and astrocytes. For representative examples of
TDP-43 proteinopathy, see Fig. 1. Mislocalized and phos-
phorylated TDP-43 is a necessary feature of LATE-NC and
sometimes has characteristics similar to those seen in type
A FTLD-TDP (Lin et al., 2009; Mackenzie et al., 2011;
Murray et al., 2014; Aoki et al., 2015), but often the fea-
tures do not fit cleanly into an established FTLD-TDP sub-
type. Indeed, a recent study described features of LATE-NC
including both similarities and differences from type A
FTLD-TDP (Josephs et al., 2019). In addition to limbic
structures, TDP-43 proteinopathy in LATE has also been
described in the olfactory bulb, neocortex, basal ganglia,
and less frequently in brainstem (Josephs et al., 2008;
Geser et al., 2010; Josephs and Dickson, 2016; Nelson
et al., 2018). Immunoelectron microscopy showed that
the TDP-43 inclusions have a fibrillary ultrastructure com-
posed of bundled 10–20-nm diameter straight filaments
(Lin and Dickson, 2008; Lin et al., 2009), often accompa-
nied by electron dense granules (Cairns et al., 2007b;
Robinson et al., 2013).
In brains with LATE-NC, haematoxylin and eosin stains
may reveal neuronal dropout and astrocytosis in the CA1
sector of the hippocampus, as well as in the subiculum,
entorhinal cortex, and amygdala (Amador-Ortiz and
Dickson, 2008). Atrophy can be marked in these areas
(Fig. 1A–C). In severely affected hippocampi, the neuropil
becomes rarefied and loss of neuronal components is
accompanied by reactive astrocytosis (Amador-Ortiz
et al., 2007a). Pronounced leucocyte infiltrates or perivas-
cular cuffing are not typically seen, but hypertrophic micro-
glia can be numerous (Bachstetter et al., 2015). The
neuronal cell loss is segmental in some subjects, observed
in some but not all sections from the same brain area
(Ighodaro et al., 2015). Hippocampal sclerosis pathology
is unilateral in 40–50% of cases in which both sides
were evaluated (Nelson et al., 2011b; Zarow et al., 2012;
Kero et al., 2018), not unlike FTLD-TDP (Irwin et al.,
2018).
Hippocampal sclerosis is present in a subset of cases with
severe LATE-NC, and was the first characteristic patho-
logical feature that distinguished it from ADNC (Dickson
et al., 1994). Nevertheless, hippocampal sclerosis is neither
specific to LATE-NC nor sufficient for the diagnosis of
LATE. The neuropathological diagnosis of hippocampal
sclerosis is fraught with difficulty. The most recent consen-
sus guidelines for ADNC and related disorders stated that
hippocampal sclerosis pathology is ‘defined by severe pyr-
amidal cell loss and gliosis in CA1 and subiculum of the
hippocampal formation that is out of proportion to AD
neuropathologic change in the same structures’ (Montine
et al., 2012). There is, however, significant topographic
and phenotypic heterogeneity in hippocampal degeneration,
creating difficulties in establishing strict criteria for wide-
spread use. Moreover, hippocampal sclerosis is a patho-
logical endpoint associated with various underlying
disease processes, including epilepsy, hypoxia, hypogly-
caemia, certain infections, and numerous neurodegenerative
conditions (Josephs et al., 2007; Thom et al., 2009; Yokota
et al., 2010; Malek-Ahmadi et al., 2013; Murray et al.,
2013; Ling et al., 2017; Popkirov et al., 2017; Sen et al.,
2018). Having originated in a 19th century study of epi-
lepsy by Wilhelm Sommer (Sommer, 1880; Thom, 2009),
the term hippocampal sclerosis is still used widely by radi-
ologists and pathologists in the context of seizure disorders
(Isnard and Bourdillon, 2015; Thom and Sisodiya, 2015).
Detailed discussions of histopathological features and sub-
types of hippocampal sclerosis can be found elsewhere
(Probst et al., 2007; Rauramaa et al., 2013; Hatanpaa
et al., 2014; Dutra et al., 2015; Thom and Sisodiya,
2015; Cykowski et al., 2017). Brains with hippocampal
sclerosis, but lacking TDP-43 pathology (TDP-43/HS + ),
do not represent LATE-NC. For example, brains with hip-
pocampal sclerosis caused by acute hypoxia or associated
with epilepsy are negative for TDP-43 proteinopathy
(Amador-Ortiz et al., 2007b; Lee and Lee, 2008; Nelson
et al., 2011b) and do not fulfil criteria for LATE-NC
(Fig. 1H). In summary, TDP-43 proteinopathy is a neces-
sary feature of LATE-NC that may or may not be accom-
panied by hippocampal sclerosis.
As has been the case in other neurodegenerative diseases
(Braak et al., 1993, 2006; Thal et al., 2000; Zaccai et al.,
2008; Alafuzoff et al., 2009), careful assessments of aut-
opsy data, from both longitudinal studies of clinic-based
research subjects as in the NIA-funded Alzheimer’s
Disease Centers, and from community-based studies, have
expanded our understanding of LATE. While subjects with
advanced age and hippocampal sclerosis often have TDP-
43 proteinopathy (Amador-Ortiz et al., 2007b; Nelson
et al., 2011b; Robinson et al., 2014; Nag et al., 2015,
2018), TDP-43 proteinopathy in limbic structures is more
prevalent than hippocampal sclerosis (Kovacs et al., 2013;
Josephs et al., 2014b; Keage et al., 2014; Murray et al.,
2014; Rahimi and Kovacs, 2014; Aoki et al., 2015; Nag
et al., 2015, 2017; Hokkanen et al., 2018; Robinson et al.,
2018b). The TDP-43-positive ( + ) and hippocampal scler-
osis-negative (HS) cases are a subset of LATE-NC that
represent 5–40% of research subjects in autopsy series.
Prior researchers have used terms for brains with TDP-43
proteinopathy and with some degree of cell dropout and
gliosis, but lacking frank hippocampal sclerosis, as a ‘pre-
cursor to HS’, ‘pre-HpScl,’ or ‘pre-HS-Aging’ (Hatanpaa
et al., 2008; Aoki et al., 2015; Hokkanen et al., 2018).
As suggested by the terminology, TDP-43 + /HS brains
may represent an early or transitional phase on the same
disease continuum as TDP-43 + /HS + cases. There are
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Figure 1 LATE neuropathological changes (LATE-NC). (A–E) Coronally sectioned human hippocampi stained using haematoxylin and
eosin (H&E). Note that the photomicrographs in A–C are presented at the same magnification. (A) LATE-NC with hippocampal sclerosis (HS).
The hippocampus is atrophic and the neuropil rarefied. (D) Higher magnification in CA1 subfield, with lack of normal cellular architecture and
with extensive gliosis. (C) Control age-matched hippocampus. (E) CA1 of the control hippocampus to demonstrate the normal cellular archi-
tecture and intact eosinophilic neuropil (asterisk). The hippocampus shown in B is less atrophic, with less obvious neuropil disruption, in
comparison to the case in A at low magnification; however, an adjacent section revealed TDP-43 proteinopathy. Hippocampal fields are labelled in
B: dg = dentate granule layer; Sub = subiculum. TDP-43 proteinopathy can be recognized using antibodies raised against either non-phos-
phorylated or phosphorylated TDP-43 epitopes. (F) Dentate granule cells in a case lacking TDP-43 pathology. Note that cell nuclei are normally
immunopositive for non-phosphorylated TDP-43 protein. In a case with LATE-NC (G), by contrast, an antibody against phosphorylated TDP-43
protein recognizes only the pathological inclusions in the nucleus (green arrow) and cytoplasm (red arrow). Unlike the antibody against non-
phosphorylated TDP-43, the antibody against phosphorylated TDP-43 is negative in non-affected cells. Most cells in G are visualized with the
counterstain, haematoxylin, which stains cell nuclei blue. The Venn diagram in H illustrates schematically the imperfect overlap between cases
with TDP-43 proteinopathy, hippocampal sclerosis, and LATE-NC. A subset of cases with TDP-43 pathology have comorbid hippocampal sclerosis
pathology; the change zone between non-hippocampal sclerosis and hippocampal sclerosis cases is indistinct because many cases seem to be in
transition with incipient hippocampal neuron loss and gliosis. Importantly, cases with hippocampal sclerosis pathology but no TDP-43
proteinopathy (e.g. hippocampal sclerosis pathology associated with anoxia or epilepsy) are not classified as LATE-NC. (I) Phospho-TDP-43
proteinopathy in two neurons in hippocampal CA1, along with phospho-TDP-43 immunoreactive dystrophic neurites. (J) Tangle-like
Consensus report: LATE BRAIN 2019: 0; 1–25 | 5
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other clues about LATE that were gathered from autopsy
cohort studies. For example, even when hippocampal scler-
osis was unilateral or segmental, the TDP-43 proteinopathy
was almost always bilateral (Nelson et al., 2011b; Ighodaro
et al., 2015). These observations have implications about
how LATE evolves, which remains an important and open
question.
Data gathered in large autopsy series have been analysed
to test hypotheses about progression of LATE.
Multivariable regression-based assessment can be used to
generate models to test whether cross-sectional data align
with proposed sequential pathways of neuropathological
changes. Results of one such pathway analysis, from the
Rush University community-based autopsy studies, are
shown in Fig. 2. These analyses were performed as
described previously (Power et al., 2018) and the findings
are compatible with at least three hypotheses: (i) a subset of
cases with TDP-43 proteinopathy develop hippocampal
sclerosis caused or exacerbated by overlapping process(s)
that promoted the TDP-43 proteinopathy, or directly by
the TDP-43 proteinopathy itself; (ii) TDP-43 proteinopathy
is associated independently with dementia, even in cases
lacking hippocampal sclerosis; and (iii) pathogenetic mech-
anisms associated with ADNC (in Fig. 2, data are provided
on neuritic amyloid-b plaques) are also associated with
increased TDP-43 proteinopathy. Current rodent models
of TDP-43 proteinopathy with hippocampal sclerosis-like
pathology are few (Ke et al., 2015). TDP-43 proteinopathy
was shown to be transmissible in mouse models similar to
pathological tau and amyloid-b from Alzheimer’s disease
brains (Porta et al., 2018), but the published TDP-43
models are thought to be more directly relevant to FTLD-
TDP than LATE. For now, the lack of adequate longitu-
dinal biomarker data and the limitations of current animal
Figure 2 Statistical analyses on data related to LATE from the Rush University community-based autopsy cohort depicting
the results of pathway analyses. Data were analysed from research volunteers (total n = 1309) in two clinical-pathological studies of ageing
from Rush University as described previously (Power et al., 2018). In this sample, the mean age of death was 89.7 years [standard deviation (SD)
6.5 years, range 65–108 years]. These analyses incorporated age, density of amyloid-b neuritic amyloid plaques (to factor in ADNC), TDP-43
proteinopathy, hippocampal sclerosis pathology, and the endpoint of Alzheimer’s-type clinical dementia. The components of the pathway analyses
most strongly associated with LATE-NC are shown in red. The numbers are path coefficients with standard error in parentheses (shown in
purple). These numbers help to quantify the effects of individual pathways. For instance, the data are compatible with there being two pathways
from TDP-43 proteinopathy to dementia, one direct pathway (TDP-43 proteinopathy!dementia) and the other indirect pathway that includes
hippocampal sclerosis pathology (TDP-43 proteinopathy!hippocampal sclerosis!dementia): in the statistical model, the TDP-43 proteinopathy
is independently associated with both hippocampal sclerosis pathology and clinical dementia status. Further, the data indicate that a subset of TDP-
43 proteinopathy is ‘downstream’ of ADNC-type neuritic amyloid plaque pathology. In a practical sense, this means that brains with more neuritic
amyloid plaques are more likely to have TDP-43 proteinopathy, with all other known factors being the same. Ab = amyloid-b.
Figure 1 Continued
phospho-TDP-43 immunoreactive cytoplasmic inclusions in amygdala (red arrows) with fewer phospho-TDP-43 immunoreactive neurites in the
background. (K) An intraneuronal phospho-TDP-43 inclusion (red arrow) and a phospho-TDP-43 deposit (green arrow) surrounding a capillary
(shown with blue arrows); these TDP-43 immunoreactive structures have been demonstrated to exist within astrocyte end-feet (Lin et al., 2009).
Note also the presence of a cell with cytoplasmic puncta (green arrow), perhaps in an early phase of phosphorylated TDP-43 proteinopathy. Scale
bar in A = 4 mm for A–C; D = 200 mm; E = 100 mm; F = 30 mm; G = 35mm; I = 30mm; and K = 25mm.
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models hamper our study of disease mechanism(s) and fur-
ther investigations are needed.
LATE MRI studies
MRI studies have provided a complementary window into
brain changes in LATE, highlighting brain atrophy both
within and outside of the medial temporal lobes of brains
with autopsy-verified LATE-NC. Prior studies featured re-
search volunteers who underwent MRI with autopsy
follow-up. Several of these studies focused on the subset
of cases with hippocampal sclerosis (i.e. presumed severe
LATE-NC), therefore, most of the published data were
lacking information about less severely affected cases.
With that caveat in mind, a common finding in MRI stu-
dies is that hippocampal atrophy is greater in cases with
LATE-NC than in those with pure Alzheimer’s disease
(Jagust et al., 2008; Josephs et al., 2008, 2017a; Dawe
et al., 2011; Kaur et al., 2014; Dallaire-Theroux et al.,
2017; Hanko et al., 2019). Barkhof et al. (2007) found
that many subjects with medial temporal atrophy lacked
primary underlying ADNC. In this study cohort, the sensi-
tivity and specificity of severe atrophy for ADNC was 63%
and 69%, respectively, consistent with prior findings (Jack
et al., 2002). Josephs et al. (2008) reported that subjects
with neuropathology consistent with LATE-NC tended to
be older, with more cognitive impairment, and with more
pronounced hippocampal atrophy than TDP-43 subjects.
Zarow et al. (2011) also described atrophy and deform-
ation of the hippocampus considerably greater in those
with hippocampal sclerosis and LATE-NC than in those
with only ADNC (Zarow et al., 2011). In hippocampal
sclerosis associated with LATE-NC, hippocampal atrophy
was often asymmetric, and it tended to progress in a ros-
tral-caudal gradient in the hippocampus. Using post-
mortem MRI, Dawe et al. (2011) reported stronger correl-
ations between hippocampal atrophy and LATE-NC (with
hippocampal sclerosis pathology) than between hippocam-
pal atrophy and ADNC, and subjects with both ADNC and
LATE-NC had greater hippocampal atrophy than those
with only ADNC. A recent study found that the volume
and shape of the amygdala is associated with underlying
LATE-NC and that these structural changes are indicative
of cognitive decline beyond what can be explained with
other pathological indices (Makkinejad et al., 2019).
Post-mortem MRI research has also provided strong evi-
dence that LATE-NC is associated with substantial brain
atrophy outside the medial temporal lobes (Kotrotsou
et al., 2015). Figure 3A shows updated data from the
Rush University autopsy cohort. After controlling for
demographics, ADNC and other age-related pathologies,
LATE-NC was related to not only the mesial temporal
lobe atrophy, but also to atrophy in the inferior frontal,
anterior temporal, and insular cortices. It is noteworthy
that this regional atrophy pattern corresponds with the dis-
tribution of TDP-43 proteinopathy at autopsy (Josephs
et al., 2016; Nag et al., 2018) (Fig. 3B). These data are
in agreement with pathological studies of LATE-NC, as
well as neuroimaging in subjects with LATE-NC risk geno-
types, showing widespread brain involvement (Neltner
et al., 2014; Cykowski et al., 2016; Josephs et al., 2016;
Nelson et al., 2016a; Nho et al., 2016).
Recommendations for routine
autopsy evaluation and classification
of LATE-NC
It is recommended that TDP-43 immunohistochemistry be
performed as part of the neuropathological evaluation in all
older subjects. At a minimum, immunohistochemical stain-
ing for TDP-43 is recommended in three brain areas: amyg-
dala, mid-level hippocampus, and middle frontal gyrus. We
recommend evaluating these regions as they are commonly
obtained at autopsy of aged subjects and capture presumed
progression of LATE-NC in the brain. This sampling in-
cludes the brain area affected early in the disease course
(amygdala, Stage 1), an intermediate stage where the patho-
logical change is robustly associated with cognitive impair-
ment (hippocampus, Stage 2), and a region affected at more
advanced stages (middle frontal gyrus, Stage 3) (Nag et al.,
2018). Any detected TDP-43 proteinopathy is sufficient to
define an anatomical region-based stage: for example, a
minute amount of detected TDP-43 proteinopathy in the
hippocampus indicates at least Stage 2. We emphasize
that the proposed sampling for LATE-NC autopsy screen-
ing is a minimal evaluation, whereas more detailed sam-
pling and staging should be considered for specific
research settings (Josephs et al., 2014a, 2016; Uchino
et al., 2015; Nag et al., 2017, 2018; Zhang et al., 2019).
Figure 3B depicts staging schemes for LATE-NC, including
sampling recommended for neuropathological evaluation of
brain of older adults. This does not address regions that
would be assessed in separate TDP-43 pathological staging
schemes developed for ALS or FTLD-TDP (Brettschneider
et al., 2013; Fatima et al., 2015; Tan et al., 2015; Verde
et al., 2017; Neumann and Mackenzie, 2019).
Practical questions arise in relation to diagnostic ‘bound-
ary zones’ between LATE-NC, FTLD-TDP, and ADNC.
While both LATE-NC and FTLD-TDP may affect neocor-
tical areas and may be comorbid with hippocampal scler-
osis, LATE-NC usually has a later age of onset, an
amnestic dementia, and limbic predominance of patho-
logical change (Nelson et al., 2011b). On the other hand,
recommendations for LATE-NC do not stipulate any age
cut-offs, because the exact age ranges of disease suscepti-
bility for FTLD-TDP or LATE-NC are not yet fully under-
stood. For prior pathology-based comparisons between
subtypes of TDP-43 proteinopathies (not related to age of
onset), previous studies should be consulted (Amador-Ortiz
et al., 2007a; Tan et al., 2015). More widespread and
severe cortical atrophy is typically present in advanced
FTLD-TDP than LATE-NC. There may indeed be features
that could definitively distinguish LATE-NC cases
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Figure 3 Brain regions that are affected in LATE. (A) Post-mortem MRI with autopsy confirmation allows discrimination of regions of
brain atrophy associated with LATE-NC. These data indicate grey matter regions inside and outside of the medial temporal lobe with atrophy in
cases with autopsy-confirmed LATE-NC from a community-based autopsy sample. The figure was prepared similarly to the methods used in
Kotrotsou et al. (2015), with some modifications. Cerebral hemispheres from 539 participants of two cohort studies of ageing (Rush Memory and
Aging Project and Religious Orders Study) were imaged with MRI ex vivo and also underwent detailed neuropathological characterization. The
cortical and subcortical grey matter were segmented into 41 regions. Linear regression was used to investigate the association of regional volumes
(normalized by height) with the score of LATE-NC at autopsy (scores: 0 = no TDP-43 inclusions, or inclusions in amygdala only; 1 = TDP-43
inclusions in amygdala as well as entorhinal cortex or hippocampus CA1, and neocortex; 2 = TDP-43 inclusions in amygdala, entorhinal cortex or
hippocampus CA1, and neocortex, and hippocampal sclerosis pathology) controlling for amyloid plaques and neurofibrillary tangles, Lewy bodies,
gross and microscopic infarcts, atherosclerosis, arteriolosclerosis, cerebral amyloid angiopathy, as well as age, sex, years of education, post-
mortem interval to fixation and to imaging, and scanners. Unique colours have been assigned to different model estimates (units: mm2) for grey
matter regions with significant negative correlation between their volumes and LATE pathology (P5 0.05, false discovery rate-corrected); darker
colours indicate greater brain atrophy in that region. Results are overlaid on both hemispheres of the T1-weighted template of the IIT Human
Brain Atlas (v.4.2). Lateral, medial and inferior to superior 3D views of the results are also shown. (B) Classification of LATE-NC according to
anatomical region(s) affected by TDP-43 proteinopathy. The present working group recommended a simplified staging scheme for routine
assessment of LATE-NC. This requires sampling and TDP-43 immunohistochemical staining of amygdala, hippocampus, and middle frontal gyrus.
More detailed TDP-43 immunohistochemical staging schemes that are directly relevant to LATE-NC were previously published by Josephs et al.
(2014a, 2016) and Nag et al. (2018). MFG = middle frontal gyrus.
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(histopathologically or molecularly) from subtypes of
FTLD-TDP (Arai et al., 2010; Hasegawa et al., 2011;
Tsuji et al., 2012; Laferriere et al., 2019); however, more
work is needed in this area. For now, definitive criteria to
differentiate severe LATE-NC from FTLD-TDP await dis-
covery of specific features that discriminate among various
TDP-43 proteinopathies (Tan et al., 2017a).
Although LATE-NC and ADNC are recognized by dif-
fering neuropathological hallmarks, they may share up-
stream risk factors and disease mechanisms. Genetic
variants predisposing to one protein misfolding disorder
may also cause or exacerbate others (see below), and
there may be interactions between the misfolded proteins
themselves (Trojanowski and Lee, 2000; Higashi et al.,
2007; Hu et al., 2008; Uryu et al., 2008; Kadokura
et al., 2009; Davis et al., 2017; Spires-Jones et al., 2017;
Tan et al., 2017b; Nelson et al., 2018). Brains that harbour
ADNC, including some subjects with early-onset familial
Alzheimer’s disease or Down syndrome, tend to also con-
tain TDP-43 proteinopathy at rates higher than those lack-
ing ADNC (Ala et al., 2000; Jellinger, 2000; Lippa et al.,
2009; Davidson et al., 2011; Zarow et al., 2012).
Individual neurons with both tau neurofibrillary tangle
pathology and TDP-43 inclusions have been described, par-
ticularly in the amygdala, entorhinal cortex, and dentate
gyrus of the hippocampus (Amador-Ortiz et al., 2007b;
Kadokura et al., 2009; Smith et al., 2017; Robinson
et al., 2018c; Josephs et al., 2019). Several published ac-
counts have evaluated the connections between primary
age-related tauopathy (PART) and age-related TDP-43 pro-
teinopathy (Josephs et al., 2017b; Smith et al., 2017;
Zhang et al., 2019), and TDP-43 proteinopathy has also
been described in brains with coexisting argyrophilic grains
or glial tauopathy (Fujishiro et al., 2009; Yokota et al.,
2010; Arnold et al., 2013; Kertesz et al., 2015). The impli-
cations of comorbid amyloid-b and various tau pathologies
in the context of LATE-NC are still incompletely under-
stood, so further studies are required. There is also evidence
that Lewy body disease and TDP-43 proteinopathy may
coexist (Nakashima-Yasuda et al., 2007; McAleese et al.,
2017; Miki et al., 2018; Trieu et al., 2018). On the other
hand, many cases with ‘end-stage’ ADNC or Lewy body
disease lack TDP-43 proteinopathy, so we recommend re-
porting the presence or absence of LATE-NC as a separate
diagnostic entity, even when there are comorbid amyloid-b,
tau and/or -synuclein proteinopathies.
Additional research is required to guide future consensus-
based recommendations in this evolving field. In terms of
immunohistochemical reagents used to detect TDP-43 pro-
teinopathy, there is no current consensus that a specific
antibody can be recommended. Many neuropathologists
use sensitive phospho-TDP-43 antibodies (Hasegawa
et al., 2008; Alafuzoff et al., 2015); small aggregates can
be readily seen using these reagents. Others use antibodies
against non-phosphorylated epitopes, especially for detect-
ing early changes (pathological nuclear to cytoplasmic re-
distribution) that may precede inclusion body formation
(Vatsavayai et al., 2016; Braak et al., 2017; Braak and
Del Tredici, 2018; Nana et al., 2019). It is unclear whether
the absence of nuclear TDP-43 is reversible, but animal
studies using inducible pathogenetic systems would suggest
so (Ke et al., 2015). Further, there is some evidence that
TDP-43 antigenicity can be vulnerable to fixation artefacts,
and epitope retrieval methodology can influence results
(Hatanpaa et al., 2008). Additional practice guidelines for
studying LATE-NC need formal blinded cross validation
studies as has been done for amyloid-b, tau and -synuclein
pathological biomarkers. Future studies will be needed to
validate and refine systems for staging LATE-NC, and
grading local pathological severity, as they relate to clinical
and neuroimaging outcomes, especially since at least
three staging schemes have been proposed as summarized
in Fig. 3B.
Clinical and neurocognitive features
of LATE
The clinical course of subjects with autopsy-proven LATE-
NC has been characterized as an amnestic cognitive syn-
drome that can evolve to incorporate multiple cognitive
domains and ultimately to impair activities of daily living,
i.e. the dementia syndrome (Nelson et al., 2010; Nag et al.,
2015; Robinson et al., 2018a, b). The cognitive impairment
is greater than can be accounted for by ADNC or other
pathologies (Gold et al., 2000; Kawas and Corrada, 2006;
Imhof et al., 2007; Giannakopoulos et al., 2008; Nelson
et al., 2011b; Kravitz et al., 2012; Boyle et al., 2013; Erten-
Lyons et al., 2013). Initial reports on subjects with LATE-
NC were focused on subjects with severe pathology
(Dickson et al., 1994; Snowdon et al., 1997; Crystal
et al., 2000; Vinters et al., 2000; Leverenz et al., 2002;
Kuslansky et al., 2004; Zarow et al., 2005, 2008; Attems
and Jellinger, 2006; Chui et al., 2006; Leverenz and Lipton,
2008), which helped to show that LATE-NC can be asso-
ciated with dementia. More recent autopsy series, with
both large sample sizes and broad ranges of clinical and
pathological findings, have enabled statistical approaches to
model the likely relative impact of each disease type. With
these methods, LATE-NC was associated with substantial
cognitive impairment that was independent of other coex-
isting pathologies (Nelson et al., 2010; Keage et al., 2014;
Murray et al., 2014; Josephs et al., 2015; Nag et al., 2017).
Table 1 shows primary data on the relationship between
LATE-NC (stratified by the recommended three-stage
system) and cognition. The neurological features associated
with LATE-NC were different from the behavioural or
aphasic clinical syndromes seen in FTLD-TDP cases
(Nelson et al., 2011b; Jung et al., 2014; Wilson et al.,
2019). While TDP-43 proteinopathy has been documented
in some cognitively unimpaired subjects (Arnold et al.,
2013; Keage et al., 2014; Uchino et al., 2015; Elobeid
et al., 2016; Nascimento et al., 2016; Nag et al., 2018;
Nascimento et al., 2018), it is likely that this represents
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preclinical disease in subjects dying before onset of clinical
symptoms; such clinical resilience to pathological changes
has been described in many disorders (Perkins et al., 2003;
Shojania et al., 2003; Roulson et al., 2005; Latimer et al.,
2017; Robinson et al., 2018b).
Although there is overlap in clinical features of autopsy-
confirmed LATE-NC and ADNC (Pao et al., 2011;
Brenowitz et al., 2014; Murray et al., 2014; Nag et al.,
2017), careful analyses may identify distinctive neurocogni-
tive features. Preliminary evidence suggests that subjects
with relatively ‘pure’ LATE-NC (lacking severe comorbid
pathologies) tend to have a more gradual clinical decline
compared to those with ‘pure’ ADNC (Murray et al., 2014;
Boyle et al., 2017). In contrast, those with comorbid
ADNC and LATE-NC showed faster decline and more
severe cognitive impairment than those with either ADNC
or LATE-NC alone (Josephs et al., 2014b, 2015; Nag et al.,
2017). In studies with both detailed longitudinal cognitive
testing and comprehensive neuropathological evaluations,
subjects with LATE-NC had prominent impairment in epi-
sodic memory (Table 1), but other cognitive domains and
global cognitive status were also commonly affected espe-
cially in the later disease stages (Nag et al., 2015, 2017,
2018; Wilson et al., 2019). Correlative studies indicate that
certain neurocognitive assessments, such as verbal fluency
measures, are not independently associated with hippocam-
pal volume, but are instead correlated with neocortical grey
matter volumes (Ajilore et al., 2015; Pelletier et al., 2017).
Correspondingly, subjects with relatively preserved verbal
fluency (cortically-dependent), despite profound deficiency
in word list delayed recall (hippocampal-dependent), have
been shown to be at risk for LATE-NC (Nelson et al.,
2011b). This pattern of neurocognitive test scores in
LATE differs from that seen in subjects with ADNC
alone (Nelson et al., 2011b) or FTLD-TDP (Brenowitz
et al., 2014).
Neuropsychiatric disturbances have been reported in
some subjects with LATE-NC (Ighodaro et al., 2015),
and a retrospective, cross-sectional, multicentre study
found evidence of increased risk of ‘agitation/aggression’
symptoms in subjects with ADNC and comorbid TDP-43
proteinopathy in comparison to subjects with ADNC lack-
ing TDP-43 proteinopathy (Sennik et al., 2017). However,
not all prior studies found that LATE-NC was associated
with non-amnestic manifestations (Velakoulis et al., 2009;
Nelson et al., 2011b; Vatsavayi et al., 2014; Sahoo et al.,
2018). Future investigations are warranted to test for spe-
cific neuropsychiatric, motor, or autonomic signs that dis-
tinguish LATE from other degenerative disorders.
Public health impact of LATE
The public health impact of LATE is likely to be quite
significant. Two basic study design elements that influence
recognition of LATE-NC in autopsy cohorts are the age
range in the cohort, and the date of the study.
Researchers were unaware of TDP-43 proteinopathy prior
to 2006, so studies prior to this time could not assess the
specific impact of LATE. LATE-NC is mostly seen in the
oldest-old, whereas in early clinical-pathological correlation
studies of dementia (Roth et al., 1966; Blessed et al., 1968),
the research subjects had died in their early 70s. LATE-NC
needs to be assessed in population studies that include all
age ranges. More recent clinical studies have demonstrated
biomarker evidence of ‘suspected non-Alzheimer’s disease
pathophysiology’ (SNAP) causing amnestic type cognitive
impairment with substantial hippocampal atrophy but lack-
ing detectable amyloid-b amyloidosis (Caroli et al., 2015;
Table 1 Selected parameters from a large community-based autopsy cohort, stratified by LATE-NC stages
Characteristics Consensus proposed LATE-NC TDP-43 stages P-value
0 1 2 3
n 666 263 258 189 -
Age at death (SD) 87.9 (6.8) 89.9 (6.2) 91.8 (5.6) 91.9 (5.4) 50.001
% Female 65.3 67.7 74 72.5 0.040
Clinical diagnosis 50.001
% Normal 41.8 33.5 18.9 7.6
% MCI or dementia 58.2 66.5 81.1 92.4
% with comorbid HS pathology 1.7 3.5 13.6 42.9 50.001
Cognitive function tests proximate to death, mean (SD)
MMSE score 22.8 (8.1) 21.2 (8.9) 18.2 (9.8) 14.0 (10.0) 50.001
Episodic memory score 0.60 (1.28) 0.76 (1.31) 1.36 (1.34) 2.06 (1.23) 50.001
Data were analysed from the Rush University ROS-MAP community-based autopsy cohort; n = 1376.
These data were analysed as described previously (Nag et al., 2018) from the Rush University Religious Orders Study (ROS), showing clinical, pathological, and cognitive status
features. The new consensus guidelines for LATE-NC staging were applied to highlight the associations between LATE-NC severity (operationalized with new recommended staging
method) including hippocampal sclerosis (HS) pathology and cognitive function tests. Note that many of these subjects in all the LATE-NC stages have additional pathologies including
ADNC as described previously (Schneider et al., 2007; James et al., 2016).
MCI = mild cognitive impairment; MMSE = Mini-Mental State Examination.
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Figure 4 Different neurodegenerative disease conditions stratified by age: LATE-NC, severe ADNC, and FTD. FTD/FTLD
cases were not present in data shown in A–D. Note that published studies to estimate disease prevalence for the various diseases have used
importantly different study designs—thus, E is a clinical (no autopsy) study because population-based autopsy cohorts lack substantial numbers of
FTD/FTLD cases. (A and B) Data from a community-based autopsy cohort—the Rush University ROS-MAP cohort (overall n = 1376). The TDP-
43 pathology is operationalized using standard methods as described previously (Nag et al., 2018) and then the current paper’s suggested simplified
staging system was applied; sample sizes for each age group (in years) are:575 (n = 34); 75–80 (n = 82); 80–85 (n = 192); 85–90 (n = 375); 90–95
(n = 407); 95–100 (n = 222); and 4100 (n = 64). Note that in this community-based sample, the proportion of cases with advanced ADNC is
550% in all age groups. (C and D) Data from the National Alzheimer’s Coordinating Center (NACC), which derives from 27 different research
centres, as described previously (Besser et al., 2018; Katsumata et al., 2018). Overall sample size is n = 806, stratified thus by age groups (in years):
575 (n = 155); 75–80 (n = 118); 80–85 (n = 165); 85–90 (n = 170); 90–95 (n = 122); 95–100 (n = 57); and 4100 (n = 19). The NACC research
subjects were more likely to come to autopsy after being followed in dementia clinics, and the sample includes a higher percentage of subjects
with severe ADNC. The percentage of subjects with LATE-NC is still420% in each age group. Note that in both the community-based cohort (A
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Burnham et al., 2016; Jack et al., 2016, 2017; Abner et al.,
2017; Wisse et al., 2018). For example, the evaluation of
1535 participants in the Mayo Clinic Study of Aging
showed significantly greater prevalence of SNAP compared
with preclinical Alzheimer’s disease, and multimorbidity
was increased in SNAP (odds ratio 2.16) (Vassilaki et al.,
2018). LATE is probably an important contributor in this
group of subjects (see below).
Among subjects autopsied past 80 years of age, most stu-
dies indicate that 420% of brains had pathological features
consistent with LATE-NC (Fig. 4). It is noteworthy that the
majority of these cases had additional comorbid pathologies,
so the measured clinical-pathological correlation (relative
contribution of each pathology to cognitive impairment)
depends on how the investigators defined diagnostic thresh-
olds and cut-points. The frequency of LATE-NC in autopsy
series have varied, ranging from 5% to 50% of brains that
were evaluated using TDP-43 immunohistochemistry, ap-
proximately twice the frequencies that were detected in
prior studies that could only assess hippocampal sclerosis
pathology (Leverenz et al., 2002; Lippa and Dickson,
2004; Arai et al., 2009; Nelson et al., 2011b; Rauramaa
et al., 2011; Tremblay et al., 2011; Corrada et al., 2012;
Zarow et al., 2012; Malek-Ahmadi et al., 2013; Keage et al.,
2014; Jellinger and Attems, 2015; Uchino et al., 2015;
Takao et al., 2016; Latimer et al., 2017; McAleese et al.,
2017; Hokkanen et al., 2018; Kero et al., 2018; Robinson
et al., 2018a). Differences in study design, including the ap-
plication of various criteria for defining pathological
abnormalities, pathological methods, recruitment strategy,
and cohort demographics, all contribute to the variability
in the reported frequency of LATE-NC.
One approach that can be used to assess the public health
impact of a disease is the evaluation of attributable risk
(Porta, 2014). Although generally used to study the impact
of risk factors on disease prevalence in a population (Bruzzi
et al., 1985), this statistical method can be applied to neuro-
pathological studies to indicate the relative impact of differ-
ent neuropathologies on clinical dementia. More specifically,
the assessment of attributable risk can query how the fre-
quency of LATE-NC, in relation to other common brain
lesions detected at autopsy, is associated with the probability
of a dementia diagnosis (Boyle et al., 2019). This analytical
approach theoretically makes it possible to estimate the pro-
portion of dementia that might be prevented if LATE-NC
could be eliminated, and to compare that with other neuro-
pathologies. The results of an analysis of attributable risk in
the Rush University Religious Orders Study is shown in
Table 2; methods have been described in detail previously
(Boyle et al., 2019). These data are compatible with the
hypothesis that a significant (15–20%) proportion of clin-
ically diagnosed Alzheimer’s disease dementia (i.e. the
Alzheimer’s clinical syndrome) in advanced age is attribut-
able to LATE-NC; the impact is about half the magnitude of
ADNC in this group of older subjects, and the impact is
similar to the combined effects of vascular neuropathologies.
Also pertinent to the current and future public health
impact of LATE is the age range of subjects with highest
risk for the disease. The tendency for LATE-NC to occur
among the oldest-old has been appreciated for decades,
since the groundbreaking studies on age-related hippocam-
pal sclerosis (Crystal et al., 1993; Dickson et al., 1994), a
pathological manifestation later shown to be associated
with LATE-NC. In multiple subsequent large autopsy sam-
ples, LATE-NC was observed with increasing frequency in
each year of life after age 85 (Nelson et al., 2013; Keage
et al., 2014; Uchino et al., 2015; Hokkanen et al., 2018)
(Fig. 4). This is in contrast to amyloid-b plaques, which are
common (seen in 450% of subjects) in all elderly age
groups, but are not universal and not more frequently
seen at autopsy with every year of advanced old age
(Braak et al., 2011; Nelson et al., 2011a, 2013;
Brenowitz et al., 2014; Neltner et al., 2016). LATE appears
to be 100-fold more prevalent than FTD syndromes,
which tend to affect younger subjects (Knopman and
Roberts, 2011; Coyle-Gilchrist et al., 2016) (Fig. 4E; note
the y-axis scale). Females are generally more likely to sur-
vive to advanced old age than males (Neltner et al., 2016),
which places them at increased lifetime risk for LATE.
Otherwise, there is no compelling evidence to date of
strong sex-related or ethnoracial differences in susceptibility
to LATE (Brenowitz et al., 2014; Murray et al., 2014;
Latimer et al., 2017; Oveisgharan et al., 2018), but further
studies in diverse populations are needed. Since most
Figure 4 Continued
and B) and clinic-based cohort (C and D), the proportion of subjects with severe ADNC decreased in advanced old age, while in the same cases
the proportion of subjects with LATE-NC increased. (E) Epidemiological data on FTD syndromes for comparison to LATE. Data are provided
about crude prevalence rates for FTD syndromes that have been associated with FTLD-TDP. Several of these clinical syndromes are likely to have
considerable numbers of cases with FTLD-tau (bvFTD and nfvPPA) or ADNC (other PPA) rather than FTLD-TDP, so the actual prevalence of
FTLD-TDP pathology is probably lower than this data suggests. Note that the clinical syndromes associated with FTLD-TDP have a prevalence
that are several orders of magnitude lower than LATE-NC. These data, described in detail previously (Coyle-Gilchrist et al., 2016), derive from
multisource referral over 2 years, which identified all diagnosed or suspected cases of FTD subtypes in two UK counties comprising the PiPPIN
(Pick’s Disease and Progressive Supranuclear Palsy: Prevalence and Incidence) catchment area in the East of England. Two cities in the PiPPIN
catchment area were Norfolk and Cambridge. Diagnostic confirmation used current consensus diagnostic criteria after interview and re-
examination. Total sample size was n = 986 483 subjects. Shown are crude prevalence rates for the major FTLD-TDP associated syndromes by age
and syndrome. bvFTD = behavioural variant frontotemporal dementia; nfvPPA = non-fluent agrammatic variant primary progressive aphasia;
svPPA = semantic variant PPA. Note that subjects between ages 55 and 80 are at greatest risk for FTD, and, the FTLD-TDP associated FTD
syndrome prevalence is 530 per 100 000 (E), in sharp contrast to the data shown in A–D.
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relevant current data were derived from autopsy cohorts,
the prevalence of LATE-NC may be higher in younger sub-
jects than currently recognized if there is a survival bias
(those with LATE-NC live to older ages), underscoring
the need for more longitudinal studies that incorporate
clinical biomarkers. Since the demographic group made
up of subjects past 85 years of age is predicted to greatly
expand in the coming decades (Gardner et al., 2013;
Nelson et al., 2013), LATE is likely to become a far greater
public health burden in the future unless preventative or
therapeutic strategies are developed.
Genetics of LATE
Genetic studies provide insights into disease-related mech-
anisms and, potentially, future therapeutic targets. The fol-
lowing five genes (in the chronological order in which they
were identified) have been reported to harbour risk alleles
associated with pathological manifestations we refer to as
LATE-NC: granulin (GRN) on chromosome 17q, trans-
membrane protein 106B (TMEM106B) on chromosome
7p, ATP-binding cassette sub-family member 9 (ABCC9)
on chromosome 12p, potassium channel subfamily M regu-
latory beta subunit 2 (KCNMB2) on chromosome 3q, and
apolipoprotein E (APOE) on chromosome 19q (Dickson
et al., 2010; Pao et al., 2011; Beecham et al., 2014;
Murray et al., 2014; Nelson et al., 2014, 2015b; Aoki
et al., 2015; Katsumata et al., 2017; Yang et al., 2018).
See Supplementary Table 1 for summary information on
these genes and their associated phenotypes. For this dis-
cussion, we include the endophenotype that was used in the
published research (usually hippocampal sclerosis) rather
than LATE-NC.
Gene variants in GRN and TMEM106B were shown to
be associated with hippocampal sclerosis and TDP-43 pro-
teinopathy risk using allele tests, based on the known
relationship of those two genes to FTLD-TDP (Baker
et al., 2006; Boeve et al., 2006; Cruts et al., 2006; Van
Deerlin et al., 2010). These gene variants have now been
most consistently associated with risk of LATE-NC. For
the association between the GRN and hippocampal scler-
osis, Dickson et al. showed that hippocampal sclerosis in
aged subjects was associated with the T-allele of the GRN
single nucleotide polymorphism (SNP) rs5848 (Dickson
et al., 2010; Murray et al., 2014). Aoki and colleagues re-
ported that the frequency of the C-allele of TMEM106B
rs1990622 in hippocampal sclerosis was lower than that
in non-hippocampal sclerosis controls (Aoki et al., 2015).
Following the initial studies, the findings were replicated of
increased risk for hippocampal sclerosis associated with each
copy of the T-allele of TMEM106B rs1990622 (Nelson
et al., 2014, 2015b; Dickson et al., 2015; Yu et al., 2015).
Since GRN and TMEM106B were both implicated in
FTLD-TDP, their strong association with LATE-NC pro-
vides compelling evidence for pathogenetic overlap between
FTLD-TDP and LATE. From a mechanistic perspective, the
cognate proteins for these genes have been shown to play
important roles in endosomal/lysosomal biology, and there
is experimental evidence for interaction of these gene prod-
ucts (Chen-Plotkin et al., 2012; Nicholson and
Rademakers, 2016; Klein et al., 2017; Zhou et al., 2017;
Paushter et al., 2018). The TMEM106B gene appears to be
pleiotropic for multiple diseases (Gallagher et al., 2014; Ou
et al., 2015; Hsiao et al., 2017; Cherry et al., 2018;
Chornenkyy et al., 2019), and the LATE-NC risk allele in
TMEM106B may influence healthy brain ageing (Rhinn
and Abeliovich, 2017; Ren et al., 2018). Separate studies
have found that GRN gene products (granulins) play roles
in inflammation and wound repair (Ahmed et al., 2007;
Miller et al., 2013). Notably, the GRN risk variant
rs5848 has been associated with increased inflammatory
mediators in CSF (e.g. AXL and CLU) (Fardo et al.,
2017). More work is required to enable better understand-
ing of how molecular pathways relevant to FTLD-TDP are
involved in LATE.
An important recent finding by several different groups is
that the APOE "4 allele, which is a risk factor for ADNC
and Lewy body disease, is also associated with increased
risk for TDP-43 proteinopathy in the elderly (Robinson
et al., 2018c; Wennberg et al., 2018; Yang et al., 2018).
Other studies did not find an association between APOE
genotypes and risk for hippocampal sclerosis (Troncoso
et al., 1996; Leverenz et al., 2002; Nelson et al., 2011b;
Pao et al., 2011; Brenowitz et al., 2014; Hall et al., 2019;
but see Farfel et al., 2016). Few subjects with the APOE "4
allele survive into advanced old age without any amyloid-b
plaques (Saunders et al., 1993; Schmechel et al., 1993), and
it remains to be seen exactly how the APOE "4 protein
influences TDP-43 proteinopathy. Nevertheless, recent stu-
dies from large research cohorts have provided additional
insights into the presence of pathogenetic mechanisms that
are shared between neurodegenerative diseases.
Table 2 A statistical analysis of attributable risk from
research volunteers in two clinical-pathological studies
of ageing from Rush University
Neuropathological indices Fraction
attributable
% (95% CI)a
Alzheimer’s disease (ADNC) 39.4 (31.5–47.4)
Vascular disease pathologyb 24.8 (17.3–32.1)
LATE-NC 17.3 (13.1–22.0)
-Synucleinopathy/Lewy body pathology 11.9 (8.4–15.6)
Shown are fractions of dementia of the Alzheimer type cases that were attributable to
individual neuropathological indices in advanced age. In this sample, the mean age of
death was 89.7 years (SD 6.5 years, range 65–108 years). For these analyses, multi-
variable logistic regression models examined associations of neuropathological indices
with the outcome of Alzheimer’s-type clinical dementia and quantified the percentage
of cases attributable to each. Methods have been described in detail previously (Boyle
et al., 2019). These data give strong indication that the public health impact of LATE is
large, on the same order of magnitude as ADNC, vascular pathologies, and Lewy body
pathology.
a95% CIs were derived using bootstrapping.
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Since the presence or absence of risk alleles in
TMEM106B, GRN, and APOE cannot by themselves or
in combination confidently predict the risk for LATE-NC in
a given subjects (Katsumata et al., 2017; Nelson et al.,
2019), there must be other factors that influence the disease
phenotype. The connections of the ABCC9 and KCNMB2
genes with risk of LATE-NC were discovered via genome-
wide association studies (GWAS), which are neither helped
nor biased by prior mechanistic hypotheses. The finding of
the associations between ABCC9 gene variants and LATE-
NC (Nelson et al., 2015b), and brain atrophy detected with
MRI (Nho et al., 2016), were reported in separate samples
from the initial GWAS (Nelson et al., 2014). Neither
ABCC9 nor KCNMB2 gene variants were associated with
LATE-NC in cohorts other than those described above.
ABCC9 and KCNMB2 are genes coding for proteins that
serve to regulate potassium channels (Zarei et al., 2007;
Nelson et al., 2015a). The ABCC9 risk genotype also im-
plicates thyroid hormone dysregulation in LATE-NC; the
locus was found to be associated with altered brain expres-
sion of genes induced by thyroid hormone (Nelson et al.,
2016a). Thyroid hormones have been found to be dysregu-
lated in subjects with autopsy-confirmed LATE-NC in
recent studies (Trieu et al., 2018; Nelson et al., 2019),
and high thyrotropin was associated with reduced hippo-
campal volume in a population-based study (Ittermann
et al., 2018). A gene variant near ABCC9, which lies
within both the SLCO1A2 and IAPP genes, was also
found in a GWAS study to be associated with neurodegen-
eration disproportional to amyloid-b accumulation
(Roostaei et al., 2016), which may indicate LATE in
those cases. The KCNMB2 gene has been associated with
suicidal ideation in US military veterans (Kimbrel et al.,
2018) and may be related to depression, which is
common in the elderly. Further, when KCNMB2 is over-
expressed in the hippocampus of mice, it rescues memory
deficits (Yu et al., 2018). More work is required to enable
better understanding and identification of the molecular
pathways involved in LATE.
Prior genetic studies on TDP-43 proteinopathy and hip-
pocampal sclerosis have varied in important ways, includ-
ing patient inclusion/exclusion criteria, disease definitions,
and age composition, which may explain their differing
findings with regard to genotype/phenotype associations.
The prospects for successful future genetic discoveries will
be improved by the development of specific and standar-
dized LATE-NC endophenotypes. FTLD-TDP provides an
example in which pathological subtyping of patients has
been beneficial for genetic correlation studies: there are,
for example, strong associations between TMEM106B
and GRN gene variants with FTLD-TDP type A pathology
(Rademakers et al., 2008; Aoki et al., 2015). Preliminary
studies suggest that distinguishing morphology of TDP-43
pathology in LATE-NC may also be relevant to genetic risk
(Josephs et al., 2019). We speculate that genetic profiling
may eventually become a key consideration for recruitment
to clinical trials, and possible future precision medicine
approaches, since some genotypes may be differentially re-
sponsive to specific interventions.
LATE biomarkers
Optimal biomarkers for LATE, including biofluids or PET
ligands, would be specific for the disease-defining feature,
namely TDP-43 proteinopathy (Steinacker et al., 2018). At
this time, no biofluid or PET biomarker satisfies this essen-
tial criterion of molecular specificity. Nor do PET ligands
for LATE seem to be on the near-term horizon. The prob-
lems of intracellular location and small pathological burden
of TDP-43 proteinopathy are obstacles that limit signal-to-
noise ratio for biomarkers.
The NIA-AA Research Framework group recommended
a system for classifying subjects based on amyloid-b amyl-
oid (A), tau (T) and neurodegeneration/neuronal injury (N)
biomarkers, which is termed AT(N) (Burnham et al., 2016;
Jack et al., 2016). Each biomarker category can be binar-
ized as positive ( + ) or negative () resulting in eight pos-
sible biomarker profiles. Certain AT(N) profiles indicate
increased likelihood that LATE-NC might be present. The
‘N’ in AT(N) is in parentheses to indicate that it represents
cumulative brain injury/neurodegeneration from all aetiol-
ogies and is not specific for any one aetiology. An assump-
tion is that in Alzheimer’s disease, neurodegeneration is
associated with tauopathy, and therefore in an
A+T(N) + subject, the N+ is likely due to a comorbid
non-Alzheimer’s disease pathophysiological process(es). If
(N) + is ascertained by an imaging measure that captures
neurodegeneration as reflected medial temporal atrophy or
hypometabolism, then this implicates LATE (often with
hippocampal sclerosis) as a likely non-Alzheimer’s disease
comorbidity. Similar logic applies to subjects with an
AT(N) + profile, the N+ is presumably due to a non-
Alzheimer’s disease pathological process(es), and if the
(N) + measure is hippocampal atrophy, or medial temporal
hypometabolism, then LATE is implicated (Fig. 5).
SNAP is a non-specific biomarker-defined category that
affects 15–30% of subjects in prior clinical series (Jack
et al., 2012; Vos et al., 2013; Wisse et al., 2015; Burnham
et al., 2016; Gordon et al., 2016), and includes a variety of
non-Alzheimer’s disease aetiologies, but prominent among
these is LATE. Autopsy studies indicate that LATE-NC can
exist without other brain pathologies, but commonly co-
occurs with ADNC (Jellinger, 2000; Attems and Jellinger,
2006; Josephs et al., 2014b, 2015, 2016); biomarker stu-
dies are consistent with those results. Botha et al. (2018)
have shown that tau-PET-negative dementia can mimic
Alzheimer’s disease clinically, suggesting that LATE is
probably a common cause of tau-negative dementia.
Further, a fluorodeoxyglucose (FDG) PET measure (the
ratio of inferior to medial temporal metabolism) was ele-
vated in autopsy proven LATE with hippocampal sclerosis
compared to autopsy proven Alzheimer’s disease cases lack-
ing LATE-NC (Botha et al., 2018). LATE-NC was con-
firmed at autopsy in two subjects with tau-PET-negative
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scans who both had elevated inferior to medial temporal
FDG metabolism ratios. These data are compatible with the
hypothesis that cognitively impaired tau-PET-negative sub-
jects with marked medial temporal hypometabolism are
likely to have LATE-NC. Other studies correlating autopsy
findings with post-mortem magnetic resonance measures of
regional tissue T2 relaxation times (Dawe et al., 2014),
hippocampal shape (Dawe et al., 2011), and regional cor-
tical volume measures (Kotrotsou et al., 2015) indicate that
neuroimaging signatures of ADNC and LATE-NC may
differ (see above). The shape differences in the medial tem-
poral lobes associated with LATE-NC versus ADNC pro-
vide potential imaging biomarkers of LATE (Dawe et al.,
2011; Makkinejad et al., 2019), whereas the evaluation
of multiple brain regions is warranted as demonstrated in
Fig. 3.
A non-specific biomarker of cumulative brain injury (N)
may be useful in the context of LATE. If a biomarker for
LATE is not forthcoming, then a quantitative in vivo indi-
cator might remain the difference between the magnitude of
an observed (N) biomarker minus the predicted (N) value
given the results of all other known biomarkers. A predict-
ive (but not diagnostic) LATE measure could be envisioned
as the ‘residual of the regression’ of expected on observed
medial/basal temporal neurodegeneration, given all know-
able information about other pathological processes.
Recent studies indicate that neurofilament light chain
(NfL) might be a preferred biofluid (N) biomarker
(Zetterberg, 2016; Kortvelyessy et al., 2018) but perturb-
ation of NfL in LATE (plasma or CSF) remains to be
tested. Moreover, elevated levels of NfL occur in many
different causes of brain injury so NfL lacks disease
specificity.
Although no specific LATE biomarker exists at present,
the AT(N) system was designed explicitly to enable expan-
sion to incorporate new biomarkers in categories beyond
AT(N) (Jack et al., 2018). If or when a biomarker of LATE
is validated, AT(N) could be expanded to ATL(N), where
‘L’ stands for LATE. The ultimate objective would be com-
prehensive characterization of many relevant brain
Figure 5 Biomarkers are currently not specific to LATE-NC. (A) Radiological scans from an 86-year-old female who suffered amnestic
cognitive impairment compatible with ‘Probable Alzheimer’s disease’ diagnosis. However, the amyloid-b PET scan was negative, tau PET scan was
also negative, and the MRI showed appreciable atrophy of the medial temporal lobes bilaterally. This combination is considered ‘ATN + ’ and
was diagnosed during life as ‘suspected non-Alzheimer’s pathology’ (SNAP). Autopsy within a year of the brain scans confirmed the presence of
TDP-43 pathology and hippocampal sclerosis, which now is diagnosable as LATE-NC. (B) Another common biomarker combination, in the brain
of a 91-year-old male with dementia. In this subject, the amyloid PET scan was positive, yet the tau PET scan was negative. The MRI again showed
atrophy of the medial temporal lobes. The combination of pathologies—in this case presumed early ADNC and comorbid LATE-NC—is
common, especially in the brains of subjects in advanced age.
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pathologies in vivo using combinations of biomarkers.
Future diagnostic biomarkers may be less centred on
ADNC, and able to incorporate the common combinations
of diseases that occur in ageing brain better. This concept is
illustrated in Supplementary Table 2.
If a specific biomarker for LATE is developed, this may
complement ongoing efforts to develop an optimal neuro-
pathological assessment. LATE-NC may in the future be
assessed along three dimensions: stage (i.e. anatomical dis-
tribution); subtype (i.e. differing histopathological patterns
in a given region); and grade (i.e. severity or pathological
load). While systems for subtyping or grading LATE-NC
have yet to be validated, these may in the future be useful
for early diagnosis, improved clinical prognosis, and devel-
opment of new strategies to treat or prevent the disease.
Implications for Alzheimer’s disease
and LATE clinical trials
Formalization of LATE diagnostic criteria and increased
awareness of this disease should help guide the design
and interpretation of Alzheimer’s disease clinical trials.
Comorbid ADNC and LATE-NC becomes increasingly
more prevalent with advancing age, and the mechanisms
underlying each of these common lesions have independent
effects on cognitive performance (Nelson et al., 2010).
LATE-NC, when coexisting with ADNC, will have the po-
tential to obscure the effects of a potential disease modify-
ing agent on cognitive assessment results in living subjects.
The primary outcome measures in disease-modifying
Alzheimer’s disease clinical trials will remain cognitive or
functional scales for the foreseeable future (Cummings
et al., 2016; Register, 2018). Thus, the presence of
LATE-NC will complicate interpretation of Alzheimer’s dis-
ease-specific treatment effects that are inferred from
observed cognitive outcomes. Until there are biomarkers
for LATE, clinical trials should be powered to account
for TDP-43 proteinopathy.
LATE is among the common age-related diseases that can
mimic the amnestic presentation of Alzheimer’s disease
(Nelson et al., 2013), and it is one of many reasons why
biological rather than clinical disease definitions are import-
ant in the era of disease modifying clinical trials (Jack et al.,
2018). Biomarkers have roles for both inclusion and exclu-
sion. It will be important, at recruitment of subjects into
future disease-modifying Alzheimer’s disease clinical trials,
to stratify according to major known predictors, including
clinical features, genetics, and known biomarkers. This
stratification will enable enrichment for subjects on the
ADNC continuum (Sevigny et al., 2016) while excluding
subjects likely to have high risk for LATE-NC (Botha
et al., 2018). Even with best efforts at baseline, the multi-
plicity of diseases that occur in brains of older subjects will
still require analyses according to subgroups. This is
another reason why clinical trials in dementing diseases
of ageing will require large sample sizes.
Research into Alzheimer’s disease has provided add-
itional topical caveats (Gulisano et al., 2018; Hunter
et al., 2018; Morris et al., 2018). For example, there is a
danger that we fundamentally misunderstand the nature
and complexity of processes related to TDP-43 proteinopa-
thy, and this could lead to significant biases in the ways
that we approach clinical diagnosis and clinical trials of
LATE. For now, as with Alzheimer’s disease, the misfolded
proteins provide a disease marker and a potential target for
therapies.
Clinical trials directed at preventing or treating LATE, in
isolation or in concert with other brain diseases, should be
a major direction for future research. Performing such trials
optimally will first require development of a specific LATE
biomarker. For now, five alternative, but not mutually ex-
clusive, approaches exist for developing disease-modifying
therapies: (i) focus on pathways and gene products such as
APOE "4 that seem to be in common between Alzheimer’s
disease, Lewy body disease, and LATE; (ii) focus on path-
ways and gene products such as TMEM106B and GRN
that are shared between FTLD-TDP and LATE; (iii) focus
on pathways and gene products such as ABCC9 and
KCNMB2 that have been implicated by GWAS; (iv) focus
on potential research subjects with the AT(N+ ) bio-
marker profile, who are now excluded from many
Alzheimer’s disease-related clinical trials; and/or (v) focus
on strategies to eliminate TDP-43 aggregates or to prevent
the formation of these aggregates.
Conclusions and future
directions
A key goal of this working group effort was to catalyse
future research on LATE, an under-recognized condition
that affects many older subjects. It is important to promote
awareness in multiple scientific areas and to focus on trans-
lational and interdisciplinary approaches.
Development of specific LATE biomarker(s) should be a
high scientific priority. While a sensitive and specific bio-
marker using neuroimaging or biofluids would be ideal,
other disease markers could capitalize on existing metrics
such as the AT(N) research guidelines with or without
imaging or biofluid risk profiling. Developing biomarkers
or other criteria to identify subjects with LATE would aug-
ment observational studies that seek to unravel the natural
history of LATE, and its coevolution with other ageing-
related diseases. With sufficient longitudinal observations,
cause and effect inferences may become possible, and clin-
ical trials implemented.
Further pathology studies will also be necessary. The
consensus pathological classification scheme that we pro-
pose should be considered preliminary because much re-
mains to be learned about LATE. The application of
pathological subtyping has been useful in the context of
FTLD-TDP (Lee et al., 2017; Mackenzie and Neumann,
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2017; Pottier et al., 2018), and pathological subtyping may
help refine LATE-NC endophenotypes for diagnostic and
genetic studies (Josephs et al., 2019). At this point, there
is no consensus about how or whether to apply such cri-
teria for LATE-NC. A detailed characterization of the mo-
lecular pathology of TDP-43 is required for different cell
types across brain regions in large population-representa-
tive samples. This should include characterization of vari-
ous phosphorylation states, cleavage fragments, and other
post-translational modifications of TDP-43. Further, each
anti-TDP-43 antibody used should be assessed for potential
cross-reactivity with other proteins or LATE-NC features in
situ. It will also be important to determine the prevalence
of all co-pathologies associated with LATE-NC, the impact
of the molecular conformations and modifications of TDP-
43, the cellular types involved, and the natural history of
the disease. These advances will also assist in developing
animal models.
Additional epidemiological, clinical, neuroimaging, and
genetic studies will be important to better characterize the
public health impact and clinical phenotypes for LATE.
Further, LATE must be studied in more diverse populations
and cohorts. Careful clinical assessments over time and into
the oldest age groups is essential, along with detailed bio-
logical measures and autopsy, so that the complexity of
ageing changes can be assessed (Brayne, 1993). In vivo
and ex vivo imaging studies to determine the focal and
more diffuse changes in the brains of subjects with LATE
will also be important. Future studies may generate better
insights into the clinical indices and cognitive features that
are associated with increased probability of LATE-NC.
Risk factors, protective influences, and other correlates
could thus be identified to help prevent or predict LATE.
For example, autoimmune disease may play a role in TDP-
43 proteinopathy and LATE-NC in particular (Miller et al.,
2013; Trieu et al., 2018). Optimally, future studies will
complement traditional GWAS and gene-focused analyses
with multi-omics studies to capture a greater appreciation
of the complex mechanisms and diagnostic or therapeutic
opportunities in the study of LATE.
Animal models and basic science research into LATE are
imperative, with the caveat that the aged human brain is
challenging to model accurately. Functional studies, includ-
ing transmission animal models that use TDP-43 fibrils
(Porta et al., 2018) or extracts from brains with LATE-
NC injected into animals or cell cultures (Laferriere et al.,
2019), can be combined with genetic studies to test hypoth-
eses and to add statistical power for preclinical and hypoth-
esis-testing experiments. Molecular studies that focus on
TDP-43 and the upstream triggers and downstream mo-
lecular consequences are necessary to elucidate mechanisms
of disease. Models that account for co-pathologies are rare
at present, but have the potential to be highly informative.
Ultimately, it is hoped that these collective research efforts
will one day result in successful preventative and thera-
peutic strategies.
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